WASHINGTON, DC: U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla in the Oval Office of the White House as he announces a deal with Pfizer to lower drug prices on September 30, ...

Pfizer (NYSE: PFE) and AstraZeneca (NYSE: AZN) had returned to the negotiating table, with a sweetened offer for the British drug maker, according to a story by The Wall Street Journal. But ...

AstraZeneca's newly-announced ambitions point to big growth ahead. At the same time, Pfizer's strategy is also proving quite ambitious. AstraZeneca isn't planning on doing as much business development ...

A Delaware federal jury has determined that AstraZeneca Plc (NASDAQ:AZN) must pay Pfizer Inc (NYSE:PFE) $107.5 million in damages, concluding that AstraZeneca’s blockbuster lung cancer drug, Tagrisso, ...

The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts, while Pfizer ...

Ediitor's note: This article was updated at 7p ET with confirmation by the White House and additional details. President Trump Friday afternoon announced that AstraZeneca has made a deal with his ...

PARIS — Health care companies Pfizer and AstraZeneca announced Sunday new investment in France worth a total of nearly $1 billion. Pfizer said it plans to invest $538.5 million in France to build its ...

Less than three months after a Delaware federal jury ordered AstraZeneca to pay $107.5 million to Pfizer in a patent infringement case, a Delaware judge has nullified the award and invalidated the ...

NEW YORK (Reuters) - At the heart of Pfizer Inc's pursuit of British drugmaker AstraZeneca Plc is a shortage of attractive products in its own research pipeline, aggravated by a recent series of ...

Pfizer upped its offer to purchase AstraZeneca Plc once again, this time to $119 billion. Pfizer calls this their final attempt, and has set a deadline of May 26th for the company to respond, but ...

As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with ...